For example, some patients treated with targeted therapies like osimertinib (a third-generation EGFR inhibitor) for non-small cell lung cancer (NSCLC) have reported disease progression or resistance over time, necessitating alternative treatments. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.